We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

89 hedge funds and large institutions have $246M invested in Cue Biopharma in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 30 increasing their positions, 30 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $1.73M | Put options by funds: $745K

14% more capital invested

Capital invested by funds: $216M → $246M (+$29.6M)

0% more funds holding

Funds holding: 89 → 89 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

0% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 30

0.18% less ownership

Funds ownership: 1.97% → 1.79% (-0.18%)

Holders
89
Holders Change
–
Holders Change %
0%
% of All Funds
1.56%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
5
Increased
30
Reduced
30
Closed
5
Calls
$1.73M
Puts
$745K
Net Calls
+$980K
Net Calls Change
+$1.84M

Top Buyers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.21M
2
GCP
GSA Capital Partners
United Kingdom
+$1.09M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1M
4
SMH
Sanders Morris Harris
Texas
+$672K
5
Morgan Stanley
Morgan Stanley
New York
+$545K

Top Sellers

Rank Fund Capital Flow
1
CA
Corriente Advisors
Texas
-$6.26M
2
WP
Woodline Partners
California
-$4.44M
3
State Street
State Street
Massachusetts
-$1.9M
4
Goldman Sachs
Goldman Sachs
New York
-$1.86M
5
Millennium Management
Millennium Management
New York
-$1.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$1.22M -$19.9K -57 -2%
Millennium Management
27
Millennium Management
New York
$1.2M -$1.71M -4,892 -64%
Charles Schwab
28
Charles Schwab
California
$1.14M -$1.41M -4,044 -61%
Stifel Financial
29
Stifel Financial
Missouri
$960K – – –
Swiss National Bank
30
Swiss National Bank
Switzerland
$911K +$24.4K +70 +3%
UBS Group
31
UBS Group
Switzerland
$854K +$367K +1,052 +117%
AC
32
Apogem Capital
New York
$754K +$44.6K +128 +8%
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$572K -$21.3K -61 -4%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$568K -$158K -452 -26%
PPA
35
Parametric Portfolio Associates
Washington
$557K +$129K +370 +41%
PM
36
Precept Management
Texas
$510K – – –
AllianceBernstein
37
AllianceBernstein
Tennessee
$487K – – –
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$472K +$16K +46 +4%
Bank of America
39
Bank of America
North Carolina
$464K +$21.6K +62 +6%
Osaic Holdings
40
Osaic Holdings
Arizona
$455K +$126K +360 +53%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$420K -$190K -544 -36%
Citigroup
42
Citigroup
New York
$411K -$639K -1,831 -66%
CM
43
Caption Management
Oklahoma
$396K – – –
HF
44
HRT Financial
New York
$396K +$316K +906 New
Marshall Wace
45
Marshall Wace
United Kingdom
$384K -$61.7K -177 -17%
Deutsche Bank
46
Deutsche Bank
Germany
$333K -$104K -297 -28%
LC
47
Lindbrook Capital
California
$291K – – –
SWM
48
SeaCrest Wealth Management
New York
$291K – – –
Barclays
49
Barclays
United Kingdom
$288K +$165K +472 +251%
WP
50
WealthShield Partners
North Carolina
$271K +$94.2K +270 +77%
1
2
3 4

CUE Hedge Fund Activity: Q3 2021 in Review

89 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2021, worth a combined $246M — up 14% from $216M a quarter earlier.

Fund positioning in CUE was balanced in Q3 2021: 5 funds opened new positions, 5 closed out, 30 added to existing stakes and 30 trimmed.

The largest buyer was Dimensional Fund Advisors, adding an estimated $1.21M. The largest seller was Corriente Advisors, cutting an estimated $6.26M.

  • 89 institutional investors held Cue Biopharma (CUE) as of Q3 2021, unchanged from Q2 2021.
  • Funds reported $246M of Cue Biopharma stock for Q3 2021, up 14% quarter-over-quarter.
  • 5 funds opened new Cue Biopharma positions in Q3 2021 and 5 closed out, a net change of 0 holders.
  • The largest Cue Biopharma buyer in Q3 2021 was Dimensional Fund Advisors, an estimated $1.21M added.
  • The largest Cue Biopharma seller in Q3 2021 was Corriente Advisors, an estimated $6.26M sold.

Based on aggregated 13F filings for Q3 2021.